# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price tar...
Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and maintains ...
Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target fro...
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(2.03) per share which missed the analyst consensus estim...
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and ...
TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from ...